Pharmafile Logo

Tobi Podhaler

- PMLiVE

Sanofi’s Aubagio backed by NICE

Oral MS drug recommended for NHS use in England and Wales

- PMLiVE

Novartis’ Tasigna tops Glivec in long-term trial

Boost ahead of patent expiry for leukaemia drug

Novartis building

Novartis myeloma drug clears phase III trial

Panobinostat on course to be first in new class of treatment for bone marrow cancer

National Institute for Health and Care Excellence NICE logo

NICE wants more info on Genzyme’s MS drug

UK health guidance body turns down Lemtrada in draft guidance

Novartis building

Novartis sets sights on eliminating leprosy

Throws weight behind meeting WHO's 2020 eradication goal

Novartis building

Scientists finds new drug target for malaria

Novartis and academics identify new class of medicines to treat all stages of infection

National Institute for Health and Care Excellence NICE logo

NICE backs two eye treatments

Novartis’ Lucentis and Alimera’s Iluvien received green light for NHS use

- PMLiVE

Scotland first in UK to back Pfizer’s Inlyta

SMC also recommends Astellas' Xtandi but not Pfizer's Bosulif

National Institute for Health and Care Excellence NICE logo

NICE denies early use of Janssen’s Velcade

Draft guidance doesn't recommend expanded bone marrow cancer indication

Novartis building

Novartis offloads diagnostics unit to Grifols for $1.7bn

Part of strategy to focus on more profitable businesses

- PMLiVE

Pfizer slams UK drug pricing plan

BioIndustry Association 
also challenges revision to PPRS

UK flag

NHS medicine spend to remain flat for two years

But UK drug pricing deal stops short of PPRS overhaul to value-based system

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links